Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
PSMA-PETgRT
PSMA-PET Guided Radiotherapy
- NCT03525288 ↗
- Active, not recruiting
- Centre hospitalier de l'Université de Montréal (CHUM)
- Focused
We haven't built an HCP commentary report on PSMA-PETgRT (Prostate Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PSMA-PETgRT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- PSMA-PET Guided Radiotherapy in Patients With High-Risk, Recurrent, or Oligometastatic Prostate Cancer
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- PSMA -PET/CT simulation; Standard-care simulation
- Arms
- PSMA-PETgRT · Experimental
- Standard · Active comparator
- Enrollment
- 130 (estimated)
- Primary outcomes
- Failure-free survival
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM) with Progenics Pharmaceuticals, Inc.
- Start
- May 15, 2018
- Primary completion
- May 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03525288 · updated Mar 13, 2025
Publications
linked from the registry- Belliveau C, Saad F, Duplan D, Petit C, Delouya G, Lambert C, Taussky D, Barkati M, Beauchemin MC, Clavel S, Mok G, Gauthier-Pare AS, Igidbashian L, Jolicoeur M, Nguyen TV, McLaughlin PY, Wong P, Keu KV, DaSilva JN, Juneau D, Menard C. PSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial. Eur Urol. 2026 Oct 3:S0302-2838(26)02413-9. doi: 10.1016/j.eururo.2026.09.017. Online ahead of print. PubMed 42829266
- Belliveau C, Saad F, Duplan D, Petit C, Delouya G, Taussky D, Barkati M, Lambert C, Beauchemin MC, Clavel S, Mok G, Igidbashian L, Gauthier-Pare AS, Nguyen TV, McLaughlin PY, Keu KV, DaSilva JN, Juneau D, Menard C. Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2025 Dec 1;11(12):1431-1438. doi: 10.1001/jamaoncol.2025.3746. PubMed 41037308
- Petit C, Delouya G, Taussky D, Barkati M, Lambert C, Beauchemin MC, Clavel S, Mok G, Pare AG, Nguyen TV, Duplan D, Keu KV, Saad F, Juneau D, Menard C. PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2023 Jul 15;116(4):779-787. doi: 10.1016/j.ijrobp.2022.12.055. Epub 2023 Jan 11. PubMed 36639035